<DOC>
	<DOCNO>NCT02874313</DOCNO>
	<brief_summary>Objectives : Main objective : To compare percentage patient new microaneurysm hard exudate 12 month CPAP group control group . Secondary objective : To compare central macula volume , ganglion cell layer thickness central fovea thickness baseline 12 , 24 52 week randomization two study group ; compare percentage patient improvement loss visual acuity ( equal 15 letter patient macular edema equal five letter patient without macular edema ) among baseline visit week 12 , 24 52 two study group ; compare percentage patient reach high level diabetic retinopathy 54 week two study group ; compare resolution time central macula thickness randomization two study group ; compare glycated hemoglobin baseline 12 , 24 52 week randomization two study group ; compare serum level inflammatory cytokine , oxidative stress biomarkers , sympathetic tone , intake regulator hormone baseline 12 52 week randomization two study group . Methodology : Randomized , multicenter , non-blinded , parallel group , conventional treatment-controlled trial 12 month duration . Subjects randomize conventional dietary pharmacological treatment conventional dietary pharmacological treatment plus continuous positive airway pressure ( CPAP ) . Study subject : Subjects 35 75 year type 2 diabetes clinical diagnosis mild diabetic retinopathy ( without macular edema ) , good visual acuity 20/40 20/320 letter refraction spherical equivalent less ± 5 diopter . Efficacy variable : Thickness central sub-field , central subfield volume , ganglion cell layer thickness , presence clinical subclinical macular edema , serous retinal retinal pigment epithelium detachment , intraretinal cyst haemorrhage assess optical coherence tomography ; presence cotton exudate , microhemorrhages , microaneurysms , , microvascular retinal abnormality , vein/artery ratio &gt; 2/1 examination ocular fundus/retinography ; well correct visual acuity ; glycosylated hemoglobin ( HbA1c ) ; fast glucose insulin ; homeostatic model assessment ( HOMA ) QUICKI index ; lipid profile , troponin I , proBNP , homocysteine C-reactive protein ; systemic biomarkers inflammation , oxidative stress , endothelial damage , sympathetic activity appetite-regulating hormone clinical questionnaire : short form ( SF ) -12 , visual function questionnaire ( VFQ25 ) iPAQ .</brief_summary>
	<brief_title>CPAP Effect Progression Diabetic Retinopathy Patients With Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Subjects age 35 75 year old . Previous diagnosis type 2 diabetes , fulfil least one follow criterion : 1 ) current treatment oral antidiabetic drug and/or insulin ; 2 ) fast glucose value 126 mg/dl least 2 occasion ; 3 ) blood glucose level 2 hour oral glucose tolerance test equal 200 mg/dl ; 4 ) glycated hemoglobin ( HbA1c ) level &gt; 6.5 % Clinical diagnosis mild nonproliferative diabetic retinopathy , without macular edema . Best correct visual acuity accord ETDRS optotype 20/40 20/320 letter 4 meter ( score 7325 letter ) study eye . Spherical equivalent refraction less ± 5 dioptre . Prior systemic treatment diabetic retinopathy , exception nutritional supplement vitamin . Pretreatment antivascular endothelial growth factor ( VEGF ) drug study eye . It allow pretreatment antiVEGF approve eye 3 month ago . Prior systemic antiVEGF , experimental approve treatment , three month inclusion . Evidence inflammation infection around study eye . Treatment troglitazone last three month . Eye surgery ( include cataract surgery ) study eye three month inclusion . Late macular degeneration ( geographical foveal neovascular involvement ) . Vascular retinal disease , vascular occlusion . Previous diagnosis eye disease could lead decrease visual acuity . Systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 110 mm Hg baseline visit . Stroke , transient ischemic attack , acute coronary syndrome , hospitalization heart failure worsening , within previous 30 day . Professional driver , risk profession respiratory failure . Severe daytime sleepiness ( Epworth sleepiness scale &gt; 18 ) Concomitant treatment high dose acetylsalicylic acid ( &gt; 500 mg/day ) continuous treatment nonsteroidal antiinflammatory drug Previous treatment CPAP Participation another clinical trial within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CPAP</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic retinopathy</keyword>
</DOC>